Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
José Baselga1,2, Ian Bradbury3,4, Holger Eidtmann5, Serena Di Cosimo2,6,7, Evandro de Azambuja8, Claudia Aura9, Henry Gómez10, Phuong Dinh11, Karine Fauria2, Veerle Van Dooren8, Gursel Aktan12, Aron Goldhirsch13,14, Tsai-Wang Chang15, Zsolt Horváth16, Maria Coccia-Portugal17, Julien Domont18, Ling-Min Tseng19, Georg Kunz20, Joo Hyuk Sohn21, Vladimir Semiglazov22
1Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
2SOLTI Breast Cancer Research Group, Barcelona, Spain
3Frontier Science (Scotland), Kincraig, UK
4Queen's University, Belfast UK
5University Hospital Kiel, Kiel, Germany
6Breast Cancer Centre, Vall d’Hebron University Hospital, Barcelona, Spain
7Vall d'Hebron University Hospital, Barcelona, Spain
8Breast European Adjuvant Study Team, Jules Bordet Institute, Brussels, Belgium
9Vall d'Hebron Institute of Oncology, Barcelona, Spain
10Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
11Breast International Group, Jules Bordet Institute, Brussels, Belgium
12GlaxoSmithKline, Collegeville, PA, USA
13European Institute of Oncology, Milan, Italy
14Swiss Centre for Breast Health, Sant’Anna Clinics, Lugano-Sorengo, Switzerland
15National Cheng Kung University Hospital, Tainan, Taiwan
16National Institute of Oncology, Budapest, Hungary
17Eastleigh Breast Care Centre, Pretoria, South Africa
18Institut Gustave Roussy, Villejuif, France
19Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan
20St. Johannes Hospital, Dortmund, Germany
21Yonsei University College of Medicine, Seoul, South Korea
22Petrov Research Institute of Oncology, St Petersburg, Russia